Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 992 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

FTC accepts Teva acquisition by Cephalon

As per the consent order, Teva should divest two Abbreviated New Drug Applications (ANDAs) for fentanyl citrate lozenges and cyclobenzaprine ER capsules. Fentanyl citrate lozenges is a generic

Merck Juvisync for Type 2 Diabetes receives FDA approval

Juvisync combines Januvia (sitagliptin), the glucose-lowering medication with the cholesterol-lowering medication Zocor (simvastatin). According to the company, Juvisync is said to provide blood sugar-lowering benefits of a DPP-4

Combivent respimat for COPD receives FDA approval

Combivent respimat, which is a propellant-free inhaler product uses a slow-moving mist to deliver the same active ingredients of Combivent Inhalation Aerosol in a metered dose inhaler (Combivent

Watson, Amphastar receive TRO on Enoxaparin

The injection product is a generic equivalent to Sanofi-aventis Lovenox. Enoxaparin is a low molecular weight heparin for treatment of deep vein thrombosis and prophylaxis of ischemic complications

Grupo Ferrer to market Alexza Adasuve

Adasuve is an anti-agitation therapeutic which combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic drug. The Staccato system is a hand-held, single-dose inhaler that delivers a drug